All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityABBs-Block Trades

Adaptimmune secures $225m of new funding

Adaptimmune_PA_575_375

Adaptimmune Therapeutics, the New York-listed UK biopharmaceutical company focused on cancer treatments, has raised $225m to fund further clinical trials for its immunotherapy treatments.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree